Cargando…

Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab

PURPOSE: To assess neurocognitive function (NCF), psychosocial outcome, health-related quality of life (HRQoL), and long-term effects of immune-related adverse events (irAE) on metastatic melanoma survivors treated with ipilimumab (IPI). METHODS: Melanoma survivors were identified within two study p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rogiers, Anne, Leys, Christophe, Lauwyck, Justine, Schembri, Adrian, Awada, Gil, Schwarze, Julia Katharina, De Cremer, Jennifer, Theuns, Peter, Maruff, Paul, De Ridder, Mark, Bernheim, Jan L., Neyns, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391091/ https://www.ncbi.nlm.nih.gov/pubmed/32775464 http://dx.doi.org/10.1155/2020/2192480

Ejemplares similares

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors
por: Rogiers, Anne, et al.
Publicado: (2019)

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
por: Awada, Gil, et al.
Publicado: (2020)

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2022)

Intratumoral Combinatorial Administration of CD1c (BDCA-1)(+) Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2020)

Exploratory study on the effectiveness of integrative neurocognitive remediation therapy (iNCRT) for cancer survivors
por: Rogiers, A., et al.
Publicado: (2022)

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS(Q61R/K/L) Mutant Melanoma (TraMel-WT)
por: Awada, Gil, et al.
Publicado: (2021)

Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1
por: Awada, Gil, et al.
Publicado: (2020)

Neurocognitive and Psychosocial Outcomes in Pediatric Brain Tumor Survivors
por: Stavinoha, Peter L., et al.
Publicado: (2018)

Psychosocial profile of pediatric brain tumor survivors with neurocognitive complaints
por: de Ruiter, Marieke Anna, et al.
Publicado: (2015)

Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse
por: Jansen, Yanina J. L., et al.
Publicado: (2021)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
por: Vermeulen, Sim, et al.
Publicado: (2021)

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
por: Awada, Gil, et al.
Publicado: (2021)

Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma
por: Thielemans, Kris, et al.
Publicado: (2014)

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
por: Wilgenhof, Sofie, et al.
Publicado: (2012)

Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
por: Lambert, Ine, et al.
Publicado: (2021)

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
por: De Keersmaecker, Brenda, et al.
Publicado: (2020)

Intratumoral administration of CD1c (BDCA-1)(+) and CD141 (BDCA-3)(+) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2022)

Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients
por: Du Four, Stephanie, et al.
Publicado: (2014)

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
por: Seremet, Teofila, et al.
Publicado: (2016)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

(18)F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
por: Wong, Annie, et al.
Publicado: (2020)

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
por: Seremet, Teofila, et al.
Publicado: (2019)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

SUN-923 Combination Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma
por: de Filette, Jeroen M K, et al.
Publicado: (2020)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
por: Sol, Bastiaan, et al.
Publicado: (2020)

Ipilimumab
Publicado: (2012)

Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis
por: Bello, Elisa, et al.
Publicado: (2019)

Psychosocial Care Needs of Melanoma Survivors: Are They Being Met?
por: Fischbeck, Sabine, et al.
Publicado: (2015)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma
por: Bar-Sela, Gil, et al.
Publicado: (2015)

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
por: de Coaña, Yago Pico, et al.
Publicado: (2017)

Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL †
por: Rogiers, Anne, et al.
Publicado: (2023)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Insomnia and Neurocognitive Functioning in Adult Survivors of Childhood Cancer
por: Tonning Olsson, Ingrid, et al.
Publicado: (2020)

Neurocognitive deficits in survivors of childhood acute myeloid leukemia
por: Takahashi, Satoko, et al.
Publicado: (2022)

AS2-2 NEUROCOGNITIVE AND PSYCHOSOCIAL DISORDERS IN CHILDREN WITH BRAIN TUMORS
por: Yoshihashi, Manabu
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7g4mg3296t82g1h587hakmhveh